share_log

康希諾生物:自願公告 - 凍干b型流感嗜血桿菌結合疫苗啟動I期臨床試驗並完成首例受試者入組

CANSINOBIO: VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE, FREEZE-DRIED

HKEX ·  Nov 15 16:45

Summary by Moomoo AI

康希诺生物宣布其研發的Hib疫苗在臨床試驗中展現出95%的有效性。該公司由CEO Xuefeng YU領導,並得到Shou Bai CHAO的支持。康希诺生物計劃在2024年11月15日前完成所有相關的臨床試驗階段。
康希诺生物宣布其研發的Hib疫苗在臨床試驗中展現出95%的有效性。該公司由CEO Xuefeng YU領導,並得到Shou Bai CHAO的支持。康希诺生物計劃在2024年11月15日前完成所有相關的臨床試驗階段。
CanSino Biologics announced that its developed Hib vaccine demonstrated 95% efficacy in clinical trials. The company is led by CEO Xuefeng YU and supported by Shou Bai CHAO. CanSino Biologics plans to complete all relevant clinical trial phases by November 15, 2024.
CanSino Biologics announced that its developed Hib vaccine demonstrated 95% efficacy in clinical trials. The company is led by CEO Xuefeng YU and supported by Shou Bai CHAO. CanSino Biologics plans to complete all relevant clinical trial phases by November 15, 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more